Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The underlying tendency is negative on the weekly chart below the resistance at 189.69 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ALLERGAN PLC5.87%58 719
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
MERCK AND COMPANY8.39%166 880
AMGEN6.39%122 422
ABBOTT LABORATORIES10.23%110 293
BAYER-2.22%108 112
GLAXOSMITHKLINE17.41%102 311
SANOFI-4.41%99 713
ELI LILLY AND COMPANY2.87%94 302
ASTRAZENECA5.12%90 821
BRISTOL-MYERS SQUIBB COMPAN..-10.57%89 573
NOVO NORDISK A/S-14.25%85 281
CELGENE CORPORATION-25.18%56 595
More Results
Financials ($)
Sales 2018 15 289 M
EBIT 2018 7 368 M
Net income 2018 -1 127 M
Debt 2018 23 406 M
Yield 2018 1,60%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,37x
EV / Sales 2019 5,06x
Capitalization 58 719 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ALLERGAN PLC
Duration : Period : Day
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Duration : Period : Week
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders